Molecular Consequences of the Auger Effect: The Fate of Iododeoxyuridine Following Iodine-125 Decay

1976 ◽  
Vol 67 (2) ◽  
pp. 224 ◽  
Author(s):  
G. Keough ◽  
K. G. Hofer
Keyword(s):  
Iodine 125 ◽  
Auger Effect

The Auger effect in biology and medicine

2012 ◽  
Vol 51 (05) ◽  
pp. 161-162 ◽  
Author(s):  
L. E. Feinendegen
Keyword(s):  
Auger Effect

Vampire Bat Salivary Plasminogen Activator Promotes Robust Lysis of Plasma Clots in a Plasma Milieu Without Causing Fluid Phase Plasminogen Activation

1992 ◽  
Vol 68 (02) ◽  
pp. 165-169 ◽  
Author(s):  
Timothy R Hare ◽  
Stephen J Gardell
Keyword(s):  
Plasminogen Activator ◽  
Plasma Levels ◽  
Fluid Phase ◽  
Immunoblot Analysis ◽  
Tissue Type ◽  
Clot Lysis ◽  
Plasma Clot ◽  
Type Plasminogen Activator ◽  
Iodine 125 ◽  
Vampire Bat

SummaryVampire bat salivary plasminogen activator (BatPA), human tissue-type plasminogen activator (tPA) or streptokinase (SK) were incubated in human citrated plasma containing a plasma clot that was radiolabelled with iodine-125 fibrin(ogen). Complete clot dissolution by BatPA (30 nM) was associated with slight activation of “fluid phase” plasminogen; the plasma levels of functional fibrinogen and α2-antiplasmin decreased by only 8 and 19%, respectively. Addition of SK (3,600 IU/ml) to the clot-containing plasma caused complete clot lysis and massive activation of the “fluid phase” plasminogen, leading to >60 and 96% decreases of the functional levels of fibrinogen and α2-antiplasmin, respectively. Incubation of tPA (30 nM) in clot-containing plasma caused complete clot lysis as well as substantial activation of “fluid phase” plasminogen; the plasma levels of functional fibrinogen and α2-antiplasmin decreased by 45 and 79%, respectively. The profound degradation of fibrinogen in the SK and tPA but not BatPA-containing samples was confirmed by immunoblot analysis. Additional experiments showed that the presence of soluble clot lysate in plasma containing tPA enhanced the extent of fibrinogen degradation from 25% to >60%; the addition of soluble clot lysate to the plasma containing BatPA did not prompt further fibrinogen degradation. Finally, studies using exogenous α2-antiplasmin suggested that plasmin generated via tPA-mediated activation of “fluid phase” plasminogen does not play an important role in clot dissolution.

Experimental Research on a Novel Iodine-125 Seed Strand Connected Using Magnesium Alloy AZ31

2014 ◽  
Vol 9 (2) ◽  
pp. 249-257
Author(s):  
Chuanxing Li ◽  
Yanling Zhang ◽  
Dong Chen ◽  
Guangfeng Duan ◽  
Zhenyin Liu ◽  
...  
Keyword(s):  
Magnesium Alloy ◽  
Experimental Research ◽  
Alloy Az31 ◽  
Magnesium Alloy Az31 ◽  
Iodine 125

scholarly journals Synthesis and Characterization of a Specific Iodine‐125‐Labeled TRPC5 Radioligand

ChemMedChem ◽  
2020 ◽  
Vol 15 (19) ◽  
pp. 1854-1860
Author(s):  
Yanbo Yu ◽  
Qianwa Liang ◽  
Lixia Du ◽  
Hao Jiang ◽  
Jiwei Gu ◽  
...  
Keyword(s):  
Synthesis And Characterization ◽  
Iodine 125

scholarly journals Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Indrawati Hadi ◽  
Daniel Reitz ◽  
Raphael Bodensohn ◽  
Olarn Roengvoraphoj ◽  
Stefanie Lietke ◽  
...  
Keyword(s):  
Risk Factors ◽  
Radiation Necrosis ◽  
Irradiation Time ◽  
External Beam Radiotherapy ◽  
High Grade Glioma ◽  
Metabolic Imaging ◽  
Time Interval ◽  
Low Grade ◽  
External Beam ◽  
Iodine 125

Abstract Purpose Frequency and risk profile of radiation necrosis (RN) in patients with glioma undergoing either upfront stereotactic brachytherapy (SBT) and additional salvage external beam radiotherapy (EBRT) after tumor recurrence or vice versa remains unknown. Methods Patients with glioma treated with low-activity temporary iodine-125 SBT at the University of Munich between 1999 and 2016 who had either additional upfront or salvage EBRT were included. Biologically effective doses (BED) were calculated. RN was diagnosed using stereotactic biopsy and/or metabolic imaging. The rate of RN was estimated with the Kaplan Meier method. Risk factors were obtained from logistic regression models. Results Eighty-six patients (49 male, 37 female, median age 47 years) were included. 38 patients suffered from low-grade and 48 from high-grade glioma. Median follow-up was 15 months after second treatment. Fifty-eight patients received upfront EBRT (median total dose: 60 Gy), and 28 upfront SBT (median reference dose: 54 Gy, median dose rate: 10.0 cGy/h). Median time interval between treatments was 19 months. RN was diagnosed in 8/75 patients. The 1- and 2-year risk of RN was 5.1% and 11.7%, respectively. Tumor volume and irradiation time of SBT, number of implanted seeds, and salvage EBRT were risk factors for RN. Neither of the BED values nor the time interval between both treatments gained prognostic influence. Conclusion The combination of upfront EBRT and salvage SBT or vice versa is feasible for glioma patients. The risk of RN is mainly determined by the treatment volume but not by the interval between therapies.

scholarly journals Optical fibre based real-time measurements during an LDR prostate brachytherapy implant simulation: using a 3D printed anthropomorphic phantom

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
P. Woulfe ◽  
F. J. Sullivan ◽  
L. Byrne ◽  
A. J. Doyle ◽  
W. Kam ◽  
...  
Keyword(s):  
Optical Fibre ◽  
Planning System ◽  
Treatment Planning System ◽  
Prostate Brachytherapy ◽  
Anthropomorphic Phantom ◽  
Optical Fibre Sensor ◽  
Ldr Brachytherapy ◽  
3D Printed ◽  
Average Activity ◽  
Iodine 125

AbstractAn optical fibre sensor based on radioluminescence, using the scintillation material terbium doped gadolinium oxysulphide (Gd2O2S:Tb) is evaluated, using a 3D printed anthropomorphic phantom for applications in low dose-rate (LDR) prostate brachytherapy. The scintillation material is embedded in a 700 µm diameter cavity within a 1 mm plastic optical fibre that is fixed within a brachytherapy needle. The high spatial resolution dosimeter is used to measure the dose contribution from Iodine-125 (I-125) seeds. Initially, the effects of sterilisation on the sensors (1) repeatability, (2) response as a function of angle, and (3) response as a function of distance, are evaluated in a custom polymethyl methacrylate phantom. Results obtained in this study demonstrate that the output response of the sensor, pre- and post-sterilisation are within the acceptable measurement uncertainty ranging from a maximum standard deviation of 4.7% pre and 5.5% post respectively, indicating that the low temperature sterilisation process does not damage the sensor or reduce performance. Subsequently, an LDR brachytherapy plan reconstructed using the VariSeed treatment planning system, in an anthropomorphic 3D printed training phantom, was used to assess the suitability of the sensor for applications in LDR brachytherapy. This phantom was printed based on patient anatomy, with the volume and dimensions of the prostate designed to represent that of the patient. I-125 brachytherapy seeds, with an average activity of 0.410 mCi, were implanted into the prostate phantom under trans-rectal ultrasound guidance; following the same techniques as employed in clinical practice by an experienced radiation oncologist. This work has demonstrated that this sensor is capable of accurately identifying when radioactive I-125 sources are introduced into the prostate via a brachytherapy needle.

Sign in / Sign up

Export Citation Format

Share Document